H.C. Wainwright analyst Douglas Tsao ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change Momentum Movers Trader Talk

Outlook Therapeutics, Inc. (OTLK) Phase 3 Data Supports Approval - AnalystAugust 3, 2021 11:54 AM Pre-Open Stock Movers 08/03: (OTLK) (TBIO) (HOLI) Higher; (CLX) (RNA) (KOPN) Lower (more...)August 3, 2021 9:22 AM Outlook Therapeutics (OTLK) Climbs 41%August 3, 2021 7:43 AM Outlook Therapeutics (OTLK) Reports Positive Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010August 3, 2021 6:03 AM Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMDAugust 3, 2021 6:00 AM Form 8-K Outlook Therapeutics, For: Jul 27July 30, 2021 4:16 PM